Postmenopause Clinical Trial
Official title:
Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin®/MPA (PREMPRO®) and MPA Suspension (Provera®) in Healthy Postmenopausal Women
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).
Status | Completed |
Enrollment | 30 |
Est. completion date | December 2007 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 35 Years to 70 Years |
Eligibility |
- Healthy postmenopausal women aged 35 to 70 years with spontaneous or surgical
amenorrhea - BMI in the range of 18 to 35 kg/m2 - History or presence of hypertension (>139 mm Hg systolic or >89 mm Hg diastolic) - History of drug allergy, particularly to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs) - Use of any prescription or investigational drug within 30 days before test article administration |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wyeth is now a wholly owned subsidiary of Pfizer | MDS Pharma Services |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma concentration data and pharmacokinetic (PK) parameters of MPA and Premarin® (estrone, equilin and MPA). | 4 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05448079 -
The Effect of Sexual Counseling Given According to the PLISSIT Model on FSFI, MAS and SQOL-F of Postmenopausal Women
|
N/A | |
Completed |
NCT00745173 -
Study Evaluating Premarin and Bazedoxifene Potential Interaction
|
Phase 1 | |
Completed |
NCT00550433 -
Study Evaluating Bazedoxifene/CE in Postmenopausal Women
|
Phase 1 | |
Completed |
NCT00913926 -
Effects of Wellnara on Climacteric Symptoms
|
N/A | |
Completed |
NCT00381251 -
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
|
Phase 1 | |
Completed |
NCT00515593 -
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
|
N/A | |
Completed |
NCT00484107 -
Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
|
Phase 4 | |
Completed |
NCT00185328 -
Efficacy and Tolerability of Angeliq in Thai Women
|
Phase 4 | |
Completed |
NCT00023543 -
Reduction of Triglycerides in Women on Hormone Replacement Therapy
|
Phase 2 | |
Completed |
NCT00152282 -
A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women
|
Phase 2 | |
Completed |
NCT00006407 -
Sex Steroid Hormones and Risk of CHD in Women
|
N/A | |
Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
Completed |
NCT00006539 -
Thrombotic, Inflammatory & Gene Markers of CVD in Women
|
N/A | |
Completed |
NCT00005515 -
Mutations, Hormone Therapy (HRT) and Venous Thromboembolism
|
N/A | |
Completed |
NCT00001752 -
Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women
|
Phase 2 | |
Completed |
NCT00000481 -
Women's Health Trial: Feasibility Study in Minority Populations
|
Phase 3 | |
Completed |
NCT00000466 -
Postmenopausal Estrogen/Progestin Interventions (PEPI)
|
Phase 3 | |
Completed |
NCT06115577 -
Endometrial Tissues and Mononuclear Cells Receptivity in Pathogenesis of Endometrial Proliferative Processes
|
||
Completed |
NCT01556737 -
Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women
|
N/A | |
Completed |
NCT00455741 -
Postmenopausal Women Estrogen and Progesterone Infusion
|
Phase 1/Phase 2 |